APA 6th Edition Kvolik, S., Ikić, V. i Jukić, M. (2011). SUGAMADEKS, NOVI ANTAGONIST MIŠIĆNIH RELAKSATORA. Liječnički vjesnik, 133 (3-4), 0-0. Preuzeto s https://hrcak.srce.hr/171665
MLA 8th Edition Kvolik, Slavica, et al. "SUGAMADEKS, NOVI ANTAGONIST MIŠIĆNIH RELAKSATORA." Liječnički vjesnik, vol. 133, br. 3-4, 2011, str. 0-0. https://hrcak.srce.hr/171665. Citirano 28.01.2020.
Chicago 17th Edition Kvolik, Slavica, Višnja Ikić i Marko Jukić. "SUGAMADEKS, NOVI ANTAGONIST MIŠIĆNIH RELAKSATORA." Liječnički vjesnik 133, br. 3-4 (2011): 0-0. https://hrcak.srce.hr/171665
Harvard Kvolik, S., Ikić, V., i Jukić, M. (2011). 'SUGAMADEKS, NOVI ANTAGONIST MIŠIĆNIH RELAKSATORA', Liječnički vjesnik, 133(3-4), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171665 (Datum pristupa: 28.01.2020.)
Vancouver Kvolik S, Ikić V, Jukić M. SUGAMADEKS, NOVI ANTAGONIST MIŠIĆNIH RELAKSATORA. Liječnički vjesnik [Internet]. 2011 [pristupljeno 28.01.2020.];133(3-4):0-0. Dostupno na: https://hrcak.srce.hr/171665
IEEE S. Kvolik, V. Ikić i M. Jukić, "SUGAMADEKS, NOVI ANTAGONIST MIŠIĆNIH RELAKSATORA", Liječnički vjesnik, vol.133, br. 3-4, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171665. [Citirano: 28.01.2020.]
Sažetak Sugammadex is a new pharmacological agent for neuromuscular block reversion. It is a cyclic oligosaccharide, a gamma cyclodextrin with lipophylic inner coat that enables forming of stable complexes with steroidal neuromuscular blocking drugs, especially with rocuronium. A physical encapsulation of the relaxants is a novel elimination pathway and it produces fast and complete reversion of both deep and shallow neuromuscular block. Consequently, sugammadex has no unwanted cholinergic muscarinic effects observed with cholinesterase inhibitors such as bradycardia, hypersalivation, and increased gastrointestinal motility. Since the effects of sugammadex are dose dependent it can very rapidly reverse the effects of rocuronium. After the adjusted dose of sugammadex was given, the duration of action of rocuronium can be made as short as that of succinylcholine. This characteristic is especially important in the ’can’t intubate, can’t ventilate’ situation and after surgical procedure was unexpectedly finished. Clinical studies involving more patients are needed to show the real risk-benefit profile and safety in the special patients’ populations